Home › Compare › ATASY vs ABBV
ATASY yields 38.55% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 4
Combined, ATASY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ATASY + ABBV for your $10,000?
As of November 25, 2022, Atlantia SpA was acquired by Schematrentatre S.P.A. Atlantia SpA, through its subsidiaries, engages in the construction and operation of motorways, airports and transport infrastructure, parking areas, and intermodal systems worldwide. It operates and manages approximately 13,000 kilometers of toll motorways. The company manages, maintains, constructs, and widens related motorways operated under concession; and provides support for the Italian motorway operators. It also operates and expands Rome's Fiumicino and Ciampino airports; and operates the airports of Nice, Cannes-Mandelieu, and Saint-Tropez. In addition, the company engages in the design, project management, controlling, and maintenance of road and airport infrastructures; and operation of toll payment systems, as well as provides assistance and toll management services. Further, it operates free-flow tolling systems, traffic and transport management systems, and electronic payment systems. Additionally, the company offers insurance brokerage, as well as engineering services. Atlantia SpA was incorporated in 1950 and is headquartered in Rome, Italy.
Full ATASY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.